Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
Karin Hehenberger, M.D., Ph.D., formerly Senior Vice President of Scientific Affairs, to Executive Vice President and Chief Medical Officer. In this new capacity, Dr. Hehenberger will be responsible for providing strategic scientific input and oversight of the company's clinical development programs and medical affairs, which expands upon her previous role of broadening the scope of proof of concept trials in autoimmune diseases for the company's lead compound TSO (Trichuris suisova or CNDO-201)
Dr. Bobby W. Sandage, Jr., Coronado's President and CEO said, "Karin's extensive clinical and industry expertise makes her an outstanding choice for Chief Medical Officer. Since joining Coronado, she has been instrumental in increasing awareness of TSO within the medical community. We look forward to Karin's leadership in our continued development of TSO for the treatment of autoimmune diseases and CNDO-109 for the treatment of cancer."
Prior to joining Coronado Biosciences, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Dr. Hehenberger joined the JDRF from Johnson & Johnson, where she served as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School and then moved into the business aspect of medicine, as a strategic management consultant at McKinsey & Co. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a Scandinavian-based venture capital company, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, and on the senior management team of Eyetech Pharmaceuticals.
